Prothena to Present New Research on Cardiac Biomarker NT-proBNP in AL Amyloidosis at HFSA Annual Meeting
15 août 2017 16h05 HE
|
Prothena Corporation Plc
Preclinical Research Demonstrating a Relationship Between Amyloid Light Chain Toxicity and NT-proBNP Production Clinical Outcomes Research Showing a Correlation between NT-proBNP and Health-related...
Prothena Reports Second Quarter 2017 Financial Results and Provides R&D Update
08 août 2017 16h05 HE
|
Prothena Corporation Plc
Net cash used in operating and investing activities was $36.3 million in the second quarter and $76.5 million for the first six months of 2017; quarter-end cash and restricted cash position of $475.8...
Prothena to Report Second Quarter 2017 Financial Results on August 8
01 août 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, Aug. 01, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
05 juil. 2017 16h05 HE
|
Prothena Corporation Plc
First potentially disease-modifying anti-alpha-synuclein antibody to be evaluated for efficacy in patients with Parkinson’s diseaseProthena to receive $30 million milestone payment under collaboration...
Prothena Announces Appointment of Wagner Zago, PhD as Chief Scientific Officer
12 juin 2017 09h00 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, June 12, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Announces Appointment of Sarah Noonberg, MD, PhD as Chief Medical Officer
16 mai 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, May 16, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena Reports First Quarter 2017 Financial Results and Provides R&D Update
09 mai 2017 16h05 HE
|
Prothena Corporation Plc
Net cash used in operating and investing activities was $40.2 million in the first quarter; quarter-end cash and restricted cash position of $510.6 million, including net proceeds of $150.3 million...
Prothena to Report First Quarter 2017 Financial Results on May 9
02 mai 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, May 02, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Prothena to Participate in the Deutsche Bank 42nd Annual Health Care Conference
26 avr. 2017 16h05 HE
|
Prothena Corporation Plc
DUBLIN, Ireland, April 26, 2017 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of...
Clinical Results Presented from Prothena’s Phase 1b Study of PRX002/RG7935 Demonstrating Robust Antibody CNS Penetration and Significant Reduction of Free Serum Alpha-synuclein in Patients with Parkinson’s Disease
02 avr. 2017 08h00 HE
|
Prothena Corporation Plc
All dose levels of PRX002/RG7935 found to have an acceptable safety and tolerability profile, meeting the primary objective of this studyRobust central nervous system (CNS) penetration demonstrated by...